NDATOPICALLOTION
Approved
Dec 2019
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
16
Data completeness
6/8 — Strong
ARAZLO (tazarotene) by Bausch + Lomb. Approved for retinoid [epc]. First approved in 2019.
Drug data last refreshed 21h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ARAZLO is a topical retinoid lotion containing tazarotene, a retinoic acid receptor (RAR) agonist with selectivity for RARβ and RARγ. It is indicated for acne vulgaris, psoriasis, and idiopathic pulmonary fibrosis, working through anti-hyperproliferative, normalizing-of-differentiation, and anti-inflammatory mechanisms. The drug was approved in December 2019 and is currently at peak commercial lifecycle.
$0.29MPart D
Peak12.0 years to LOEModest Part D volume ($290K, 526 claims in 2023) suggests niche positioning with limited mainstream adoption; commercial team likely focused on dermatology and specialty channels.
Mechanism of Action
Pharmacologic Class:
Retinoid
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (16)
Combination of Halobetasol Propionate and Tazarotene Lotion (Duobrii®) for Palmoplantar Plaque Type Psoriasis
Started Nov 2020
22 enrolled
Palmoplantar PsoriasisPlaque Psoriasis
Topical Tazarotene Vs Placebo In Hand-Foot-Skin Reactions
Started Dec 2019
8 enrolled
Solid TumorHand-Foot Skin Reaction (HFSR)
A Study to Assess the Safety and Local Tolerability of DFD-03 (Tazarotene) Lotion, 0.1% Compared to Tazorac® Cream, 0.1% in the Topical Treatment of Acne Vulgaris
Started Aug 2017
155 enrolled
Acne Vulgaris
Efficacy and Safety of Tazarotene Gel in Nail Psoriasis
Started Feb 2014
66 enrolled
Nail Psoriasis
A Study to Evaluate the Potential of Tazarotene Foam to Cause an Allergic Reaction When Applied to the Skin and Exposed to Light on Healthy Volunteers.
Started Jun 2010
59 enrolled
Acne Vulgaris
Worked on ARAZLO at Bausch + Lomb? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.